Keio University Graduate School of Health Management, 4411 Endo, Fujisawa-shi, Kanagawa, 252-0883, Japan.
Statistics Analysis Department 1, EPS Corporation, 6-85 Shinogawa-machi, Shinjuku-ku, Tokyo, 162-0815, Japan.
BMC Psychiatry. 2020 Mar 12;20(1):118. doi: 10.1186/s12888-020-02525-z.
Little is known regarding the association between adverse events (AEs) and psychiatric medications administered to pregnant women in clinical trials during the pre-marketing period. This study analyzes reports of AE association with psychiatric medication administrated during pregnancy using post-marketing spontaneous reports of AE from the Japanese Adverse Drug Event Report (JADER) database and Food and Drug Administration Adverse Event Reporting System in the United States (FAERS-US).
We summarized AE reports of psychiatric medication administrated during pregnancy by comparing data obtained from JADER and FAERS-US databases with medication patterns determined as classes via latent class analysis. The odds ratios (ORs) of AE reports categorized into system organ classes in which each class was compared with those without psychiatric medications.
The proportions of AE reports under psychiatric medication in pregnancy among all AE reports were 22.0% and 16.6% in JADER and FAERS-US, respectively. The 10,389 reports of psychiatric medication during pregnancy were classified into 11 classes. The proportion of patients receiving four or more psychiatric drugs in JADER was larger than that in FAERS-US. The maximum number of reports in combinations of AE and medication pattern in JADER was 169, for 'general disorders and administration site conditions' from the class of four or more medications (OR = 9.1), while that in FAERS-US was 1,654, for 'injury, poisoning, and procedural complications' from the class of single psychiatric medication (OR = 2.8).
The main AE reports and associated AE differed depending on medication patterns in pregnant women taking psychiatric medication. This study may provide a prediction of AEs that are likely to be reported with each medication pattern. Our findings of the association between AE reports and medication patterns could help improve the administration of psychiatric medications during pregnancy, though further research on additional datasets is needed to clarify these results.
在上市前临床试验期间,关于孕妇接受的不良事件(AE)与精神药物之间的关联,人们知之甚少。本研究通过比较日本不良药物事件报告(JADER)数据库和美国食品药品监督管理局不良事件报告系统(FAERS-US)中上市后自发报告的 AE 与妊娠期间精神药物使用的报告,分析与妊娠期间使用的精神药物相关的 AE 报告。
我们通过潜在类别分析确定药物类别,将 JADER 和 FAERS-US 数据库中的数据与药物模式进行比较,总结妊娠期间精神药物使用的 AE 报告。将每个类别与没有精神药物的类别进行比较,以分类为系统器官类别的 AE 报告的比值比(OR)。
JADER 和 FAERS-US 中,妊娠期间精神药物 AE 报告占所有 AE 报告的比例分别为 22.0%和 16.6%。妊娠期间的 10389 例精神药物报告分为 11 类。JADER 中接受 4 种或更多精神药物的患者比例大于 FAERS-US。JADER 中 AE 与药物模式组合的报告数量最多为 169,为 4 种或更多药物类别的“一般疾病和给药部位情况”(OR=9.1),而 FAERS-US 中报告数量最多为 1654,为单一精神药物类别的“损伤、中毒和程序并发症”(OR=2.8)。
服用精神药物的孕妇的主要 AE 报告和相关 AE 因药物模式而异。本研究可能为每种药物模式下可能报告的 AE 提供预测。我们对 AE 报告与药物模式之间的关联的发现可以帮助改善妊娠期间精神药物的管理,但需要对其他数据集进行进一步研究,以澄清这些结果。